For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Pinealon: origin, structure and research history

Research Library › Bioregulators & Thymic

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (glutamic acid, aspartic acid, arginine), also written EDR. It was developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, with a Russian patent priority date of May 2006. As of October 2026 it is not approved as a drug by the FDA or the European Medicines Agency, and the evidence base is mostly preclinical.

Key facts

TypeSynthetic tripeptide (three amino acids)
SequenceH-Glu-Asp-Arg-OH (EDR)
Other namesEDR peptide, glutamyl-aspartyl-arginine
First describedRussian patent RU2301678, priority 30 May 2006; earliest indexed journal reports 2008
Developed byVladimir Khavinson and colleagues, Saint Petersburg Institute of Bioregulation and Gerontology, Russia
Designed targetNo specific receptor identified; proposed in cell studies to act on gene expression
Regulatory status (Oct 2026)Not FDA-approved; not EMA-authorized; not named individually on the 2026 WADA Prohibited List

Who developed it

Pinealon comes from the laboratory of Vladimir Khavinson, the Russian gerontologist who led the Saint Petersburg Institute of Bioregulation and Gerontology and later a peptide research group at the Pavlov Institute of Physiology [1, 2]. The group has spent several decades studying short peptides it calls “bioregulators”, a family that also includes Epitalon and other di-, tri- and tetrapeptides.

The tripeptide H-Glu-Asp-Arg-OH was claimed in a Russian patent application filed on 30 May 2006 (RU2301678), naming Khavinson, Evgeny Grigoriev, Vladimir Malinin and Galina Ryzhak as inventors. The same patent family was later extended internationally, including a US patent granted in 2013 [3].

Structure and design

Pinealon is one of the smallest peptides in the Khavinson catalog: just three amino acids, L-glutamic acid, L-aspartic acid and L-arginine, joined in that order. Its molecular formula is C15H26N6O8, with a molar mass of about 418 g/mol [4]. In the group’s 2011 paper it is described simply as a synthetic tripeptide [1].

A 2021 review by the same group states that the EDR sequence was identified within Cortexin, a polypeptide preparation derived from animal brain tissue that is registered as a drug in Russia [2]. The name “Pinealon” suggests a link to the pineal gland, but the cited primary literature describes its origin in terms of Cortexin rather than pineal tissue.

No dedicated receptor for pinealon has been found. The Khavinson group has proposed that very short peptides can enter cells and the nucleus and interact with DNA or chromatin, a hypothesis based on cell-culture and fluorescence-labeling work [5]. This proposed mechanism has not been confirmed by independent groups.

Research history

Almost all published pinealon research comes from Russian institutions, much of it from the Khavinson group and its collaborators, and much of it appears in the Russian-language journal Advances in Gerontology. The work is mainly preclinical: cell-culture experiments and rat studies [1, 6]. A small number of Russian observational reports in people exist, but no randomized controlled trial of pinealon has been registered or published in an international journal.

  • 2006: Russian patent application for H-Glu-Asp-Arg-OH filed [3]
  • 2008: Earliest PubMed-indexed report studying the peptide, on short peptides in hypoxia models [6]
  • 2011: First English-language cell study under the name pinealon, in Rejuvenation Research [1]
  • 2013: US Patent 8,524,674 granted [3]
  • 2021: Review proposes a gene-expression mechanism for the EDR peptide [2]

Regulatory status as of October 2026

Pinealon is not approved as a drug by the US Food and Drug Administration or authorized by the European Medicines Agency. It does not appear in FDA drug approval records, and no human trial of it is registered on ClinicalTrials.gov. The cited primary literature does not describe any Russian drug registration for pinealon itself, as distinct from Cortexin [2].

Pinealon is not named individually on the 2026 WADA Prohibited List, whose section S0 covers pharmacological substances not approved for human therapeutic use [7]. The underlying US patent was listed as expired for non-payment of fees [3].

About this reference page

Kalibra Labs does not currently supply Pinealon. This page is published as a neutral scientific and regulatory reference. Browse the Bioregulators & Thymic guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

What is the amino acid sequence of pinealon?

Pinealon is the tripeptide Glu-Asp-Arg (glutamic acid, aspartic acid, arginine), written EDR in one-letter code [1, 3].

Who developed pinealon?

It was developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology, Russia; the founding patent application was filed in May 2006 [3].

Is pinealon FDA approved?

No. As of October 2026 pinealon is not approved by the FDA or authorized by the EMA, and its published evidence is mainly preclinical.

Is pinealon made from the pineal gland?

No. It is a synthetic peptide. The developers’ 2021 review says the EDR sequence was identified within Cortexin, a brain-derived polypeptide preparation [2].

Sources

  1. Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535–541. doi:10.1089/rej.2011.1172. Link
  2. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules. 2021;26(1):159. doi:10.3390/molecules26010159. Link
  3. Khavinson VKh, Grigoriev EI, Malinin VV, Ryzhak GA. US Patent 8,524,674 B2 (claims H-Glu-Asp-Arg-OH); priority RU2301678, 30 May 2006; granted 3 Sep 2013. Family includes WO2007139431 and EP2024388. Link
  4. PubChem. Pinealon, CID 10273502 (Glu-Asp-Arg; C15H26N6O8). National Library of Medicine. Link
  5. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011. PMID 22117547. Link
  6. Kozina LS. [Investigation of antihypoxic properties of short peptides]. Adv Gerontol. 2008. PMID 18546825. Link
  7. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top